Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$47.3 - $70.6 $38,833 - $57,962
821 Added 0.38%
219,623 $10.6 Million
Q2 2023

Aug 14, 2023

SELL
$48.26 - $78.59 $5.61 Million - $9.13 Million
-116,191 Reduced 34.68%
218,802 $14.9 Million
Q1 2023

May 15, 2023

BUY
$46.97 - $58.27 $1.1 Million - $1.37 Million
23,493 Added 7.54%
334,993 $16.2 Million
Q4 2022

Feb 14, 2023

BUY
$52.05 - $65.0 $7.45 Million - $9.3 Million
143,100 Added 84.98%
311,500 $18.8 Million
Q3 2022

Nov 14, 2022

BUY
$25.16 - $60.63 $1.72 Million - $4.15 Million
68,500 Added 68.57%
168,400 $10.2 Million
Q2 2022

Aug 15, 2022

SELL
$22.73 - $39.98 $1.66 Million - $2.92 Million
-73,100 Reduced 42.25%
99,900 $2.71 Million
Q1 2022

May 16, 2022

SELL
$30.27 - $49.22 $611,454 - $994,244
-20,200 Reduced 10.46%
173,000 $6.33 Million
Q4 2021

Feb 14, 2022

BUY
$42.11 - $73.26 $1.32 Million - $2.29 Million
31,300 Added 19.33%
193,200 $9.54 Million
Q3 2021

Nov 15, 2021

SELL
$48.2 - $78.89 $332,580 - $544,341
-6,900 Reduced 4.09%
161,900 $11.5 Million
Q2 2021

Aug 16, 2021

BUY
$21.63 - $57.65 $3.65 Million - $9.73 Million
168,800 New
168,800 $8.68 Million
Q3 2020

Nov 16, 2020

SELL
$9.93 - $13.47 $2.64 Million - $3.58 Million
-265,573 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$9.56 - $12.51 $2.39 Million - $3.13 Million
-250,470 Reduced 48.54%
265,573 $2.78 Million
Q1 2020

May 15, 2020

BUY
$7.54 - $15.77 $1.46 Million - $3.06 Million
193,743 Added 60.11%
516,043 $5.52 Million
Q4 2019

Feb 14, 2020

BUY
$7.48 - $17.01 $2.41 Million - $5.48 Million
322,300 New
322,300 $5.1 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $701M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.